key: cord-0833429-66vuebe6 authors: Hussain, Musaddique; Jabeen, Qaiser; Ahmad, Fiaz-Ud-Din; Kashif-Ur-Rehman,; Fatima, Mobeen; Shaukat, Saira; Majeed, Abdul; Barkat, Muhammad Qasim; Wu, Ximei title: COVID-19 and inhibitors of the renin–angiotensin–aldosterone system date: 2020-11-26 journal: Expert review of anti-infective therapy DOI: 10.1080/14787210.2021.1851197 sha: c2e7a9f8f56fb3d84e3e2dfb632200cd051accc7 doc_id: 833429 cord_uid: 66vuebe6 nan Severe acute respiratory syndrome coronavirus 2 (SARS-CoV -2), main cause of coronavirus disease 2019 (COVID- 19) , uses the aminopeptidase angiotensin-converting enzyme 2 (ACE2) for entry into the host cell. ACE2, part of the renin-angiotensin-aldosterone system (RAAS), is abundantly expressed in heart, lungs, and other tissues. ACE inhibitors (ACEI) and angiotensin-receptor blockers (ARBs) are considered first-choice drugs in hypertension, post-myocardial infarction states, heart failure, and chronic kidney disease. Multicenter study has revealed that hypertension, coronary artery disease, and diabetes are the most frequent comorbidities in severe COVID-19 patients than nonsevere illness [1, 2] . Various preclinical and clinical studies have speculated that ACEI and/or ARBs could theoretically worse outcomes via increasing the ACE2 expression for SARS-CoV-2 entry into the host cell [3, 4] . These speculated discoveries have stimulated discussions about whether ACEI and ARBs may potentially treat COVID-19 or, conversely, worsen disease [5, 6] while arguments need aroused potential concerns. This hypothesis gained traction via social media and medical press. For instance, COVID-19 patients with hypertension and diabetes could be at increased risk of severe coronavirus symptoms [7] and are four times as likely to die [8] if they are taking one of these drugs, prior to coronavirus exposure. Anxiety among physicians and patients has been profound because ACEI and ARBs are the most widely prescribed drugs globally for treatment of hypertension, heart disease, and chronic kidney disease, and also increase the expression of ACE2 [9, 10] . In this regard, clinicians are weighing the alleged harm of continuing these medications in patients for whom ACE inhibitors and ARBs have known benefit against the harm to their cardiovascular and kidney health associated with discontinuing them. In this rapidly evolving setting, many observational studies [11] [12] [13] [14] [15] [16] with the looming possibility of confounding and largest meta-analysis [17] [18] [19] were conducted in different populations with different designs to access whether ACEI and/or ARBs are indeed harmful in the context of the COVID-19 epidemic. Importantly, message obtained from all of these observational studies and meta-analysis was consistent because none of these provide evidence to support the hypothesis that neither ACEI nor ARBs were associated with the increased risk for SARS-CoV-2 infection, severe illness, or death [11] [12] [13] [14] [15] [16] . Secondary analysis involving hypertension patients also did not show harm between these drugs and severe COVID-19. Additionally, several other smaller studies conducted in the United Kingdom and China also revealed same conclusion [20] [21] [22] . Unexpectedly, Francisco et al. [11] and Mehra et al. [12] revealed that the use of either ACEI and/or ARBs or statins may be associated with a lower risk of in-hospital death than nonuse, but neither of the other studies revealed such effect. Other studies have also suggested that the use of RAAS inhibitors might confer protective effects against complications and death in patients with COVID-19 versus other antihypertensive drugs, although these studies were not restricted to patients with diabetes [21, 22] . These outcomes may be due to the absence of a randomized trial and unmeasured confounding, and should not be regarded as evidence to prescribe these drugs in COVID-19 patients. Taken together, several professional societies and experts have put forward their guidance with one voice that COVID-19 patients should not discontinue ACEI or ARB therapy during the COVID-19 pandemic [23, 24] because complications due to the indiscriminate discontinuation of these drugs could have far more serious consequences than many of the surmised adverse effects. In short, we would strongly encourage hypertensive patients to continue with RAAS inhibitor pharmacotherapy during the COVID-19 pandemic. Clinical characteristics of coronavirus disease 2019 in China Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention Chappell MCCOVID-19. ACE2, and the cardiovascular consequences Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19 Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Chronic use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers is high among intensive care unit patients with non-COVID-19 sepsis but carries a moderately increased risk of death Medicines taken by 6.6 million people with high blood pressure and diabetes could raise the risk of deadly coronavirus symptoms, scientists claim. Daily Mail Perhaps 4X more likely to die of COVID-19 if take ACE inhibitors (reduce blood pressure). VitaminDWiki Pharmacologic modulation of ACE2 expression Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 Use of reninangiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study Cardiovascular disease, drug therapy, and mortality in COVID-19 Renin-angiotensin-aldosterone system blockers and the risk of Covid-19 Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19 Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study RAAs inhibitors and outcome in patients with SARS-CoV-2 pneumonia. A case series study Effect of renin-angiotensinaldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 patients Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: a systematic review and meta-analysis Effect of renin-angiotensinaldosterone system inhibitors on outcomes of COVID-19 patients with hypertension: systematic review and meta-analysis. medRxiv Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19 Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China Renin-angiotensinaldosterone system inhibitors in patients with Covid-19 HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19